2021-11-16-世界卫生组织-Cervical_cancer_Saint_Lucia_2021_country_profile_1页_64kb

Morbidity and Mortality: In 2020, the crude cervical cancer incidence was 21.5 per 100,000 women, and the age-standardized incidence was 16.6 per 100,000 women. The cumulative risk of cervical cancer by age 74 was 2.2%. In 2019, there were 590 deaths from cervical cancer, and the mortality-to-incidence ratio in 2020 was 0.65. No population-based cancer registry exists (as of 2021). Total female population in 2019 was 93,000, with 590 female deaths in 2019.

Primary Prevention: HPV vaccination is included in the national vaccination programme, introduced at 11-12 years with a primary target cohort of girls aged 9-14. In 2020, 59% of girls in the target cohort were vaccinated with final doses by age 15. Coverage was 74% in 2019 by that age. Related risk factors include a tobacco use prevalence of 0.65% among women aged 15+ in 2020, but data on condom use and HIV incidence are not available.

Secondary Prevention Screening: A national screening programme for cervical cancer does not exist (as of 2021), but cytology is used for primary screening, targeting women aged 15-49. Approximately 79% of women in this age group have been screened in the last five years, with 92% ever screened (concentrated in women aged 30-49). A system to strengthen early detection and referral from primary to secondary and tertiary care exists.

Treatment and Supportive Care: National guidelines for cervical cancer management exist (as of 2021), with available resources including cancer centres at tertiary levels. Specific details on radiotherapy, chemotherapy, and staff availability are not fully specified, but palliative care for non-communicable diseases is accessible in the public health system.

WHO Elimination Strategy Targets: Data align with global targets for 2030, including reducing incidence and mortality, though full details are limited. Radiation and other staff numbers are from years past, but specifics are incomplete.